Summit Corporation plc Stock London S.E.
Equities
GB00B02T3K57
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
05-01 | Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 | |
05-01 | Summit Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.28B 2.86B 3.92B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.88% |
Latest transcript on Summit Corporation plc
Managers | Title | Age | Since |
---|---|---|---|
Mahkam Zanganeh
CEO | Chief Executive Officer | 52 | 20-11-10 |
Robert Duggan
CEO | Chief Executive Officer | 79 | 19-11-30 |
Director of Finance/CFO | 46 | 19-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Duggan
CEO | Chief Executive Officer | 79 | 19-11-30 |
Robert Booth
BRD | Director/Board Member | 70 | 22-09-27 |
Director of Finance/CFO | 46 | 19-11-30 |
1st Jan change | Capi. | |
---|---|---|
-1.30% | 103B | |
+7.87% | 101B | |
+4.40% | 23.07B | |
-12.22% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.63% | 16.94B | |
+6.85% | 14.07B | |
+38.63% | 12.35B |